Your browser doesn't support javascript.
loading
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer, Jacobus; Shannon, Catherine M; Baumann, Klaus; Rau, Joern; Harter, Philipp; Joly, Florence; Sehouli, Jalid; Canzler, Ulrich; Schmalfeldt, Barbara; Dean, Andrew P; Hein, Alexander; Zeimet, Alain G; Hanker, Lars C; Petit, Thierry; Marmé, Frederik; El-Balat, Ahmed; Glasspool, Rosalind; de Gregorio, Nikolaus; Mahner, Sven; Meniawy, Tarek M; Park-Simon, Tjoung-Won; Mouret-Reynier, Marie-Ange; Costan, Cristina; Meier, Werner; Reinthaller, Alexander; Goh, Jeffrey C; L'Haridon, Tifenn; Baron Hay, Sally; Kommoss, Stefan; du Bois, Andreas; Kurtz, Jean-Emmanuel.
Afiliação
  • Pfisterer J; Gynaecologic Oncology Center, Kiel, Germany. Electronic address: jacobus.pfisterer@googlemail.com.
  • Shannon CM; Oncology Department, Mater Cancer Care Centre, Brisbane, QLD, Australia.
  • Baumann K; Gynaecology Department, Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen, Germany.
  • Rau J; Coordinating Center for Clinical Trials, Philipps-University, Marburg, Germany.
  • Harter P; Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany.
  • Joly F; Gynaecology Department, Centre François Baclesse, Caen, France.
  • Sehouli J; Department of Gynaecology, and European Competence Center for Ovarian Cancer, Charité - Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany.
  • Canzler U; Department of Gynaecology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Schmalfeldt B; Technical University of Munich-Klinikum Rechts der Isar, Germany; Department of Gynaecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Dean AP; Gynaecological Oncology Department, St John of God Hospital, Subiaco, WA, Australia.
  • Hein A; Gynaecology Department, Erlangen University Hospital, Erlangen, Germany.
  • Zeimet AG; Department of Obstetrics and Gynaecology, Innsbruck Medical University, Innsbruck, Austria.
  • Hanker LC; Gynaecology Department, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
  • Petit T; Paul Strauss Cancer Center and Gynaecology Department, University of Strasbourg, Strasbourg, France.
  • Marmé F; Gynaecology Department, National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany; Department of Gynaecology and Obstetrics, University Hospital Mannheim, Mannheim, Germany.
  • El-Balat A; Department of Gynaecology and Obstetrics, University of Frankfurt/Main, Frankfurt, Germany.
  • Glasspool R; National Cancer Research Institute, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK.
  • de Gregorio N; Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany.
  • Mahner S; Department of Gynaecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Obstetrics and Gynaecology, University Hospital, Ludwig-Maximilian-University, Munich, Germany.
  • Meniawy TM; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Park-Simon TW; Department of Gynaecology and Obstetrics, Medical University Hannover, Hannover, Germany.
  • Mouret-Reynier MA; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.
  • Costan C; Department of Oncology, Hôpital Michallon, Grenoble, France.
  • Meier W; Department of Gynaecology and Obstetrics, Evangelisches Krankenhaus Düsseldorf, Germany; Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
  • Reinthaller A; Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Centre, University Hospital for Gynaecology, Medical University Vienna, Vienna, Austria.
  • Goh JC; Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia.
  • L'Haridon T; Centre Hospitalier Départemental les Oudairies, La Roche-Sur-Yon, France.
  • Baron Hay S; Women's Health, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Kommoss S; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • du Bois A; Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany.
  • Kurtz JE; Haematology-Oncology Department, Centre Hospitalier Régional et Universitaire de Strasbourg Hôpital Civil, Strasbourg, France.
Lancet Oncol ; 21(5): 699-709, 2020 05.
Article em En | MEDLINE | ID: mdl-32305099
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias das Tubas Uterinas / Bevacizumab / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa / Oceania Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias das Tubas Uterinas / Bevacizumab / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa / Oceania Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article